Start-up develops novel next-generation immuno oncology treatments
Bayer and Northpond Ventures lead USD 55 million Series A financing round
31-Aug-2020 -
Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD 55 million Series A financing round. The financing was co-led by Leaps by Bayer, the impact investment unit of ...
cancer
cancer therapy
Series A financing
+2